# Almirall, S.A. clinical trials: 66 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 66 trials with Almirall, S.A. as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Almirall, S.A.: 66 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/almirall-s-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 66
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 66, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 14, 2026 | NCT07873801 | A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis | Almirall, S.A. | Phase 3 | Not yet recruiting | Atopic Dermatitis | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873801) |
| April 23, 2026 | NCT07547813 | A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa | Almirall, S.A. | Phase 2 | Recruiting | Hidradenitis Suppurativa | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547813) |
| April 21, 2026 | NCT07542483 | A Study of Lebrikizumab in Adults With Nummular Eczema | Almirall, S.A. | Phase 3 | Recruiting | Nummular Eczema | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07542483) |
| March 13, 2026 | NCT07471932 | A Study of LAD106 in Healthy Adult Participants | Almirall, S.A. | Phase 1 | Recruiting | Healthy Volunteers | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07471932) |
| December 31, 2025 | NCT07311564 | A Study of LAD603 in Adults With Alopecia Areata | Almirall, S.A. | Phase 2 | Recruiting | Alopecia Areata | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07311564) |
| September 3, 2025 | NCT07151937 | A Study of LAD191 in Adults With Hidradenitis Suppurativa | Almirall, S.A. | Phase 2 | Recruiting | Hidradenitis Suppurativa | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07151937) |
| February 7, 2025 | NCT06815380 | A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With... | Almirall, S.A. | Observational | Recruiting | Atopic Dermatitis, Eczema | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06815380) |
| July 29, 2024 | NCT06526182 | A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | Almirall, S.A. | Phase 3 | Active not recruiting | Dermatitis, Atopic, Eczema | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06526182) |
| July 5, 2024 | NCT06488209 | Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease | Almirall, S.A. | Phase 1 | Completed | Healthy Volunteers, Autoimmune Disease | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06488209) |
| July 5, 2024 | NCT06488170 | A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting | Almirall, S.A. | Observational | Active not recruiting | Plaque Psoriasis | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06488170) |
| January 11, 2024 | NCT06200597 | A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects | Almirall, S.A. | Phase 1 | Completed | Healthy Volunteers | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06200597) |
| November 18, 2023 | NCT06135415 | A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis | Almirall, S.A. | Phase 3 | Completed | Keratosis, Actinic | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06135415) |
| September 8, 2023 | NCT06030076 | A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants... | Almirall, S.A. | Observational | Recruiting | Plaque Psoriasis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06030076) |
| September 8, 2023 | NCT06029257 | A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO) | Almirall, S.A. | Observational | Recruiting | Genital Psoriasis | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06029257) |
| August 14, 2023 | NCT05990725 | Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | Almirall, S.A. | Phase 3 | Completed | Atopic Dermatitis, Eczema | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05990725) |
| June 23, 2023 | NCT05916365 | Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis | Almirall, S.A. | Phase 3 | Completed | Atopic Dermatitis | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05916365) |
| April 13, 2023 | NCT05811234 | A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of... | Almirall, S.A. | Observational | Completed | Plaque Psoriasis | 291 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05811234) |
| February 23, 2023 | NCT05741294 | A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses | Almirall, S.A. | Phase 4 | Completed | Actinic Keratosis | 334 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05741294) |
| August 1, 2022 | NCT05481073 | UV Sensor in Patients With Actinic Keratosis | Almirall, S.A. | Observational | Completed | Keratosis, Actinic | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05481073) |
| May 24, 2022 | NCT05387525 | A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or... | Almirall, S.A. | Phase 4 | Active not recruiting | Keratosis, Actinic | 447 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05387525) |
| March 15, 2022 | NCT05279131 | A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis | Almirall, S.A. | Phase 3 | Completed | Keratosis, Actinic | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05279131) |
| March 2, 2022 | NCT05260073 | Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis | Almirall, S.A. | Observational | Completed | Keratosis, Actinic | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05260073) |
| December 8, 2021 | NCT05149313 | A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately... | Almirall, S.A. | Phase 3 | Completed | Dermatitis, Atopic, Eczema | 331 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05149313) |
| March 30, 2021 | NCT04823247 | Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study | Almirall, S.A. | Observational | Completed | Plaque Psoriasis | 782 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04823247) |
| March 29, 2021 | NCT04820673 | Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES) | Almirall, S.A. | Observational | Completed | Acne Vulgaris | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04820673) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 1 |
| Phase 2 | 17 |
| Phase 3 | 22 |
| Phase 4 | 7 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 53 |
| Recruiting | 8 |
| Active not recruiting | 3 |
| Terminated | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Keratosis, Actinic | 14 |
| Psoriasis | 12 |
| Acne Vulgaris | 8 |
| Dermatitis, Atopic | 7 |
| Skin Diseases | 6 |
| Eczema | 5 |
| Keratosis | 4 |
| Dermatitis | 4 |
| Precancerous Conditions | 3 |
| Neoplasms | 3 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Hidradenitis Suppurativa | 2 |
| Asthma | 1 |
| Signs and Symptoms | 1 |
| Hidradenitis | 1 |
| Infections | 1 |
| Respiratory Tract Infections | 1 |
| Alopecia Areata | 1 |
| Alopecia | 1 |
| Hypotrichosis | 1 |
| Tinea Pedis | 1 |
| Multiple Sclerosis | 1 |
| Muscle Spasticity | 1 |
| Skin Diseases, Eczematous | 1 |
| Autoimmune Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Asian restaurants in the United States](https://specstream.ai/data/businesses/asian-restaurants/united-states)
- [Packing services in the United States](https://specstream.ai/data/businesses/packing-services/united-states)
- [Doner kebab restaurants in the United States](https://specstream.ai/data/businesses/doner-kebab-restaurants/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
- [Jewelry and watches manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-and-watches-manufacturers/united-states)
- [Building contractors in the United States](https://specstream.ai/data/businesses/building-contractors/united-states)
